MDS experts, Dr Alan List and Dr David Sallman, provide an overview of the use of lenalidomide for myelodysplastic syndromes (MDS). This treatment is highly effective in patients with the chromosome 5q deletion type of MDS. It may also be used in lower-risk MDS patients. They also discuss the potential side effects of lenalidomide.
Share with family and friends:
Click here to take our Myelodysplastic Syndromes (MDS) SURVEY Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.
This educational activity has been developed by
the Myelodysplastic Syndromes Foundation, Inc and Mechanisms in Medicine Inc.
This activity is supported by charitable grants from Celgene Corporation, Jazz Pharmaceuticals, Novartis, and Takeda Oncology.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their health care professionals for optimal outcomes.